PEG-MGF
⚠️ Structural Separation Notice
The Ageless Pep Academy is a clinical education property independent from any commerce operation. Any references in this profile to Ageless Peps product SKUs, pricing, or the agelesspeps.com domain are for completeness and transparency; they are not endorsements and do not form part of the clinical education content. Clinicians are responsible for independent verification of any product sourcing decision. The Academy's Medical Director provides editorial oversight only and does not endorse commercial products.
PEGylated Mechano Growth Factor; IGF-1Ec splice variant E-domain peptide with polyethylene glycol modification extending half-life from minutes to 48-72 hours. Activates muscle satellite cells for hypertrophy and injury repair.
Quick Facts
| Property | Value |
|---|---|
| Also Known As | PEG-MGF, Pegylated Mechano Growth Factor, Pegylated IGF-1Ec |
| Category | Recovery / GH Axis |
| Sequence | IGF-1Ec E-domain peptide (24 amino acids) + PEG chain |
| Molecular Weight | ~2800 Da (peptide) + PEG chain |
| Molecular Formula | Variable (PEG chain length dependent) |
| PubChem CID | N/A (PEGylated research compound) |
| Administration | SubQ / IM |
| Typical Dose Range | 200-400 mcg, 2-3x/week |
| Half-Life | 48-72 hours (vs minutes for native MGF due to PEGylation) |
| Storage | Lyophilized -20C 1-2 years; reconstituted 2-8C 2-3 weeks |
| FDA Status | Research-only (not approved) |
| WADA Status | Prohibited (S2 — Peptide Hormones, Growth Factors) |
Mechanism of Action
Mechano Growth Factor (MGF) is a splice variant of insulin-like growth factor-1 (IGF-1) generated specifically in skeletal and cardiac muscle in response to mechanical loading (exercise) and tissue damage. The IGF-1 gene undergoes alternative splicing to produce the IGF-1Ec isoform, whose unique C-terminal E-domain peptide (the MGF peptide) has biological activity distinct from mature IGF-1. Native MGF has an extremely short half-life of only minutes due to rapid proteolytic degradation, making systemic administration impractical. PEGylation (covalent attachment of polyethylene glycol chains) extends the half-life to 48-72 hours by shielding the peptide from proteases and reducing renal clearance. PMID 20130113
The MGF E-domain activates muscle satellite cells — the resident stem cells required for muscle hypertrophy and regeneration — through a receptor distinct from the classical IGF-1R. This activation drives satellite cell proliferation and migration to sites of muscle damage, followed by upregulation of myogenic transcription factors MyoD and myogenin to promote myoblast differentiation and new muscle fiber formation. The N-terminal domain retains IGF-1R agonist activity, stimulating protein synthesis via the mTOR pathway. PMID 15501012
MGF also demonstrates cardioprotective effects, reducing loss of cardiac function after myocardial infarction through anti-apoptotic signaling and cardiomyocyte protection. PMID 17581790
Recent research has shown MGF accelerates anterior cruciate ligament repair through Rac1-RhoA signaling pathway modulation, suggesting applications beyond muscle to connective tissue repair. PMID 35457148
MGF modulates inflammatory cytokine expression during muscle regeneration, downregulating TNF-alpha and IL-1beta while upregulating IL-10, creating a pro-regenerative immune environment. PMID 30140235
Key Research Areas
- Muscle Aging and Sarcopenia: MGF expression declines with age; exogenous supplementation may restore satellite cell activation capacity. PMID 15501012
- Tissue Repair: Comprehensive review of MGF in skeletal muscle, cardiac, and connective tissue repair. PMID 20130113
- Cardiac Protection: Reduces functional loss after myocardial infarction. PMID 17581790
- Ligament Repair: Accelerates ACL repair via Rac1-RhoA signaling. PMID 35457148
- Inflammatory Modulation: Shifts cytokine profile toward regeneration during muscle healing. PMID 30140235
Evidence Level Summary
| Evidence Type | Count | Notes |
|---|---|---|
| Human RCTs | 0 | No human RCTs; all studies on MGF, not PEG-MGF specifically |
| Human observational | 0 | — |
| Animal in vivo | 3 | Cardiac MI model, ACL repair, muscle regeneration |
| In vitro | 1 | ACL cell signaling |
| Systematic reviews | 0 | — |
| Narrative reviews | 2 | Tissue repair review, muscle aging review |
Clinical Applications
- Injury Recovery — Satellite cell activation for muscle repair
- Muscle Tears — Myoblast differentiation and fiber regeneration
- Sarcopenia — Age-related decline in MGF expression
- Tendon and Ligament Repair — ACL and connective tissue repair via Rac1-RhoA
- Post-Procedure Recovery — Muscle atrophy prevention
Protocols Using This Peptide
Ageless Peps Products
- AP-PEGMGF-Vial — PEG-MGF Vial (PEGylated), $76
- AP-MGF-Vial — MGF Vial (non-PEGylated native form), $35 (draft status)
- AP-WOLVERINE-Blend — Wolverine Blend (BPC-157 + TB-500 + MGF), $109
Dosing Reference
Research Dosing Ranges (from literature)
| Route | Dose Range | Frequency | Duration | Source |
|---|---|---|---|---|
| SubQ/IM | 200-400 mcg | 2-3x per week | 4-8 week cycles | Practitioner guides |
| IM (local) | 200 mcg | Post-workout or at injury site | 4-8 weeks | Practitioner guides |
Cycling
4-8 week cycles with timing post-workout for maximum satellite cell response. PEGylation concern: theoretical PEG accumulation with chronic use; cycle lengths mitigate this. Rest periods of 4-8 weeks between cycles recommended.
Contraindications & Safety
- Contraindications: Active malignancy (absolute — satellite cell activation could theoretically promote tumor cell proliferation); pregnancy/breastfeeding (insufficient data)
- Common side effects: Mild injection site reactions; generally well tolerated
- Drug interactions: No significant known interactions; theoretical synergy with GH secretagogues
- Pregnancy/nursing: Insufficient data; avoid
- Special populations: PEG accumulation is a theoretical concern with chronic use; standard cycle lengths (4-8 weeks) mitigate this risk
Synergistic Combinations
- BPC-157 + TB-500 + PEG-MGF — AP-WOLVERINE-Blend comprehensive recovery: angiogenesis + tissue repair + satellite cell activation
- CJC-1295 NO DAC + Ipamorelin + PEG-MGF — GH axis + satellite cell activation
- IGF-1 LR3 + PEG-MGF — IGF-1R stimulation + satellite cell-specific activation
Related Research
| PMID | Title | Year | Study Type |
|---|---|---|---|
| 20130113 | Mechano-Growth Factor: Tissue Repair Review | 2010 | Review |
| 15501012 | Growth Factors and Muscle Ageing: MGF | 2004 | Review |
| 17581790 | MGF Reduces Loss of Cardiac Function Post-MI | 2007 | Animal in vivo |
| 35457148 | MGF Accelerates ACL Repair via Rac1-RhoA | 2022 | In vitro |
| 30140235 | MGF Modulates Inflammatory Cytokines in Muscle Regeneration | 2018 | Animal in vivo |
References
- PMID 20130113 — Tissue repair review
- PMID 15501012 — Muscle aging review
- PMID 17581790 — Cardiac MI model
- PMID 35457148 — ACL repair
- PMID 30140235 — Inflammatory cytokines
Related
#peptide #recovery #gh-axis #subq